Volume 2 ; Issue 1 ; in Month : Jan-June (2019) Article No : 116
Kim MK

Abstract

Objective: After the JGOG 3016 trial, several studies have evaluated the effectiveness of dose-dense paclitaxel and carboplatin for advanced ovarian carcinoma. The objective of this study was to compare dose-dense paclitaxel and carboplatin (dd-TC) to conventional paclitaxel and carboplatin (c-TC) regarding chemotherapy-induced toxicity and quality of life (QoL) using EORTC questionnaire serially through six cycles of adjuvant chemotherapy. Materials and Methods: Patients who received six cycles of either c-TC (carboplatin AUC(Area Under Curve) 5 mg/mL on day 1 and paclitaxel 175 mg/mL every 3 weeks) or dd-TC (carboplatin AUC 6 mg/mL on day 1 and paclitaxel 80 mg/m² on days 1, 8, and 15) were selected. Patients’ QoL was measured using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC QLQ-C30) version 3.0 and its ovarian-specific module QLQ-OV28. Clinical information was extracted from medical records. Results: This study included 17 patients, including 8 in the c-TC group and 9 in the dd-TC group. The dd-TC regimen was associated with higher frequency of gastrointestinal toxicity. Other chemotherapy-induced toxicities or patient QoL were not statistically significantly different between the two treatment arms. Conclusions: Patients treated with dd-TC or c-RC regimen have comparable tolerability and quality of life.

Full Text Attachment

Views : 504      Downloads : 15

RSS